alpidem has been researched along with ssr180575 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benavides, J; Bourliaud, G; Brault, E; Claustre, Y; Ferzaz, B; Fournier, J; George, P; Liere, P; Marabout, B; Marguet, F; Nowicki, JP; Poughon, G; Robert, JP; Scatton, B; Schumacher, M; Sevrin, M; Soubrie, P | 1 |
1 other study(ies) available for alpidem and ssr180575
Article | Year |
---|---|
SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair.
Topics: Acetamides; Aging; Animals; Anti-Anxiety Agents; Axotomy; Binding, Competitive; Cell Survival; Facial Nerve; GABA-A Receptor Agonists; GABA-A Receptor Antagonists; Humans; Imidazoles; Indoles; Ligands; Male; Motor Neurons; Neuroprotective Agents; Pyridazines; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, GABA-A | 2002 |